Resolved, that IPO opposes the Affordable Prescriptions for Patients Act of 2023 (S. 150), which would create per se antitrust liability for the introduction of improved pharmaceutical products via “hard switches” and “soft switches” and could discourage innovation and result in fewer improved products and choices for patients.